Among the immune checkpoint inhibitors, PD-1/PD-L1 and CTLA-4 inhibitors significantly improved survival and clinical manifestation in preclinical models of sepsis [18,19,20], which lead to their testing in a human clinical trial of severe sepsis [20]. The gene discussed is CTLA4; the disease is Sepsis.